Introduction {#Sec1}
============

Chronic medication management is essential in order to provide optimal care for the older orthopedic surgical patient. The purpose of the study reported here was to provide guidance to health care professionals on medication management during the perioperative period.

In 2015, global life expectancy at birth was 76.8 years in the World Health Organization (WHO) European Region \[[@CR1]\]. The prevalence of comorbidities in the elderly is high, with 80% of this population having three or more chronic conditions \[[@CR2]\]. Increases in longevity and the prevalence of associated pathologies are reflected in the fact that most hospital admissions involve chronic patients with multiple pathological problems \[[@CR3], [@CR4]\]. The rising population aged more than 64 years has also resulted in a higher than expected prevalence and incidence of bone fractures \[[@CR5]\].

In recent years, a significant proportion of medication errors have occurred during transitions between levels of care, especially during admission and discharge \[[@CR6]\]. In 2005, the WHO launched the Action on Patient Safety initiative, also known as the High 5s project, to address issues related to the safety of patients around the world \[[@CR7]\]. This initiative includes, among others, a protocol to assure medication accuracy at transitions in care or medication reconciliation. In hospitals that implemented this protocol, the morbidity and mortality associated with medication errors were reduced by 32% \[[@CR8]\].

Kennedy et al. \[[@CR9]\] carried out a prospective survey to identify drug usage/withdrawal in surgical patients and its relationship to the relative risk for postoperative surgical complications. The researchers concluded that at least 50% of patients who were undergoing surgery took medications on a regular basis that were not related to their surgery. Moreover, they stated that withdrawing regular medicines may significantly increase the risk of surgery and further complicate the outcome.

Clinicians must often decide whether chronic medications should be continued during the perioperative period. Unfortunately, there is a lack of medical evidence in this regard, which is reflected in considerable variability in perioperative management recommendations. Kroenke et al. \[[@CR10]\] assessed opinions regarding the preoperative discontinuation or modification of selected medications by mailing a questionnaire to all 150 anesthesiology program directors in the United States. The responses highlighted great variation in practice medication management, reflecting a lack of firm evidence favoring any one approach.

Among orthopedic surgical patients, it is very important to individually evaluate the risk/benefit of maintaining or suppressing chronic medications, which will depend partly on the drug and the type of surgical intervention, but most importantly on the clinical status of the patient \[[@CR11]\]. However, given the lack of sound evidence on this topic, clinicians base their decisions on expert opinions, isolated clinical cases, or theoretical considerations based on experience with similar drugs \[[@CR12]\].

Hence, it is necessary to gather together and evaluate the available recommendations for maintaining or suppressing chronic medications during the perioperative period \[[@CR13], [@CR14]\], and then to use this information to produce a guide for the continuity of care in perioperative medication management. Such a guide could help hospital pharmacists to ensure the continuity of chronic pharmacotherapeutic treatment, thereby avoiding unnecessary interruptions and searches for therapeutic alternatives. However, this guide would not be a substitute for clinical judgment and experience.

The aim of the present study was therefore to develop (by reviewing the available evidence) and to validate a new guide for the continuity of care in perioperative medication management, which could aid pharmacists and surgeons who need to manage chronic medications in older adults during the perioperative period.

Materials and methods {#Sec2}
=====================

Study design {#Sec3}
------------

The development of the guide for the continuity of care in perioperative medication management was based on a literature search and an external review by an expert committee. The guide was validated through a prospective, noninterventional cohort study. The flow of the study process is illustrated in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Study design

### Development of the guide {#Sec4}

The guide was formulated by an expert pharmacist (CM) by systematically reviewing the available evidence for each medication class, based on the Anatomical Therapeutic Chemical (ATC) classification system developed by the European Pharmaceutical Market Research Association \[[@CR15]\]. It includes the most consumed ATC pharmacological subgroups according to data for the year 2014 from the Ministry of Health, Social Services and Equality of Spain \[[@CR16]\].

Recommendations were based on three concepts: the pharmacokinetics of the drug, the effect of withdrawing the medication on the primary disease, and the effect of the medicine on the perioperative risk, including potential interactions with anesthetic agents.

For the literature search, a consistent process was applied, based on:Drug information (technical data sheet).Micromedex^®^. Provides summaries and detailed monographs for drugs, diseases, alternative medicine, toxicological managements, reproductive risks, and emergency care. It includes the following drug information databases: DRUGDEX^®^ system. Dosage, pharmacokinetics, cautions, interactions, clinical applications, and comparative drug efficacy.MARTINDALE. Electronic version of the Martindale textbook published by the Royal Pharmaceutical Society of Great Britain. Offers extensive information on international drug products. Especially useful when searching for European drugs, and can be searched by brand name or generic name.Alternative medicine. Includes monographs on herbal, vitamin, mineral, and other dietary supplements, based on scientific evidence as well as historical and common uses.UptoDate^®^. An evidence-based, physician-authored clinical decision support resource that clinicians trust to make the right point-of-care decisions. Muluk and Macpherson provide an overview of preoperative patient assessment as well as details about the perioperative management of specific medications \[[@CR12]\].PubMed^®^. Online database of biomedical journal citations and abstracts. The search strategy was similar to that applied by Lievanos Rojas in his thesis *Perioperative management of chronic medications in orthopaedic surgery. A systematic review of the literature* \[[@CR17]\].

Finally, an external multidisciplinary review of the guide was performed by members of the Pharmacy and Therapeutics Committee at the Hospital General Universitario de Elche, including surgical specialists and physicians from the Department of Anesthesiology, who contributed their experience in clinical practice.

### Validation of the guide {#Sec5}

The guide was validated by performing an interobserver variability study.

Participants {#Sec6}
------------

An expert pharmacist (CM) with 15 years of experience in the pharmacotherapeutic validation of medical orders was responsible for developing the guideline, and acted as the gold standard. She determined the correct action to perform regarding usual chronic treatments in the perioperative environment according to the clinical status of the patient.

The observers comprised eight pharmacists with different levels of professional experience who were working in the same hospital. There were three staff pharmacists, all of whom had clinical and pharmacological knowledge and a wide range of experience in the pharmacotherapeutic validation of medical orders; five resident pharmacists, two of whom were residents in their first year and thus had little knowledge of the practical application of drugs; and three other resident pharmacists in their second or third year of residency, who had more experience in validating the pharmacotherapeutic profiles of patients.

Training course {#Sec7}
---------------

The course was given by the expert (CM). The concepts covered in the session addressed the following five questions:*Why was the guide created?* She explained that the purpose of the guide was to ensure the continuity of pharmacotherapeutic information, reduce variability in clinical practice, exceed the needs of the patient at all times during the perioperative period by improving safety, and improve the efficiency of the medication utilization process.*How is the guide structured?* She presented a brief summary of the format of the guide, including its structure according to the ATC classification, as well as the benefits and risks of continuing or discontinuing medication in the perioperative environment.*How are the chronic medications grouped according to perioperative recommendations?* She described simple concepts for the following situations:3.1.Drugs that can increase morbidity if they are discontinued abruptly. Their use should continue in the perioperative period, or the treatment can be adjusted if possible.3.2.Drugs that increase the risk of anesthetic medications or complications during surgery and which are not essential in the short term. These drugs should be suspended during the perioperative period.3.3.Drugs that do not belong to any of the previous groups. These may be suspended or continued according to clinical criteria.*What basic pharmacological concepts do we need to know?* She gave participants a brief overview of the most relevant drug interactions as well as descriptions of metabolic processes and the elimination of drugs and their metabolites, and she discussed how these can be altered in the perioperative period.*How should I act if I have any doubt?* She stressed the importance of agreeing with clinic staff (either the orthopedic surgeon responsible for the patient or another relevant medical specialist) on the action to be taken in the event of clinical instability of the patient, or if there is doubt about the typical chronic treatment.

Source of patients {#Sec8}
------------------

Patients admitted to an orthopedic surgery unit in a Spanish tertiary 450-bed hospital from August 1 to September 1, 2016, were included in the validation study. The number of chronic medications required for the study was calculated based on the sample size required to detect a kappa value that was significantly different from zero with 90% power. We aimed for a power of 90% in a two-tailed test for a kappa value of at least 0.6, where we estimated that the guidelines would have greater than 90% concordance with the views of the expert pharmacist. The calculated value was based on assessments of over 30 drugs \[[@CR18]\]. Therefore, 140 drugs were analyzed in 20 patients (seven drugs per patient).

Study procedure {#Sec9}
---------------

Each observer (i.e., pharmacist) received a dossier containing drug therapy and clinical information about each of the 20 patients to whom the guide was to be applied. The information about the patients comprised the following: the patient's ID number (1--20), age, sex, personal history, diagnosis-related drugs (DRGs), date of surgical intervention, and chronic treatment. The form included specific instructions that had to be marked with an X depending on whether the decision was made to continue (C) or suspend (S) treatment for the patient according to the guide for the continuity of care in perioperative medication management and the clinical information about the patient.

Patient treatments were reviewed blindly and independently by the eight pharmacists and compared with the gold standard (CM).

Statistical analysis {#Sec10}
--------------------

Statistical analyses were carried out using the software SPSS for Windows 20.0 (IBM SPSS). Cohen's kappa, with a confidence interval (CI) of 95%, was used to analyze the concordance between each observer and the expert and between the eight observers. The degree of concordance was expressed as a numerical value of*k*, which ranged from 0.0, indicating absolute discordance, to 1.0, indicating perfect concordance. A value of \> 0.61 indicated that the agreement was good \[[@CR19]\]. For each item in the scale, the percent agreement was calculated as the number of times that the raters agreed on a rating (continue/discontinue) divided by the total number of ratings.

Results {#Sec11}
=======

Development of the guidelines {#Sec12}
-----------------------------

Some of the information reviewed came from clinical trials, but most was based on the opinions of experts, isolated clinical cases, or theoretical considerations according to experience with similar drugs \[[@CR12]\]. There are consensus recommendations for several medications, whereas information is limited or controversial for others. Therefore, it is very important to assess the risk/benefit ratio in each case, and it is possible that the final decision will not coincide with the general recommendations. For each drug, we selected several articles reviewing the full text of all relevants.

After reviewing the available information on the perioperative management of chronic medications in order to develop the guide, Table [1](#Tab1){ref-type="table"} was created. It divides the drugs into 12 main anatomical groups, 51 therapeutic groups, and a phytotherapy revision group.Table 1Perioperative management of medicationsClassBenefits in continuing therapyRisks in continuing therapyConsiderationsRecommendation*A: Alimentary tract and metabolism* A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)Prevents stress-related mucosal damage caused by surgery, decreases gastric volume and raises gastric fluid pH, reducing the risk of chemical pneumonitis from aspirationPPIs increase the risk of*Clostridium difficile* infectionEssential prior to anesthesiaContinue as usual A03A: Drugs for functional gastrointestinal disordersPromotes gastric emptyingNo known perioperative adverse effectsBaseline ECG required to document QT intervalContinue as usual A06: Drugs for constipationNo known perioperative adverse effectsContinue as usual A07E: Intestinal antiinflammatory agentsIncreased bleeding risk due to antiplatelet effectsDiscontinue A10A: Insulins and analoguesHyperglycemia increases the risk of perioperative infectionsInduces hypoglycemiaBasal insulin therapy is necessary in all insulin-treated diabetic patientsContinue with adjustments A10B: Blood-glucose-lowering drugs excl. insulinsAvoids perioperative hyperglycemiaSignificant risk of hypoglycemia\
*Metformin:* contraindicated in conditions that increase the risk of renal hypoperfusion, lactate accumulation, and tissue hypoxia\
*Thiazolidinediones:* could precipitate congestive heart failure due to fluid retention and peripheral edema\
*DPP4 inhibitors and GLP*-*1 analogs*: alter gastrointestinal motilityMonitor blood glucose frequentlyShould be taken until the day before the operation but discontinued the day of the operation A12: Mineral supplementsEnsure that electrolyte balance is controlledDiscontinue*B: Blood and blood-forming organs* B01: Antithrombotic agentsIncreased bleeding riskRefer to perioperative management of antiplatelet therapy guide B03A: Iron preparationsConstipation risk in bedridden patients, which is increased with opioid therapySevere iron-deficiency anemia may require a blood transfusionDiscontinue B03B: Vitamin B12 and folic acidDiscontinue*C: Cardiovascular system* C01AA: Digitalis glycosidesManagement of underlying atrial fibrillation or congestive heart failureNarrow therapeutic window. Check digoxin levelsContinue as usual C01BD: Antiarrhythmics, class IIIPossibility of recurrence of arrhythmias if stoppedBradycardia, electrolyte imbalances may exacerbate risk of QT prolongation with amiodarone*Amiodarone:* long half-lifeShould be continued until and including the day of the operation C01DA: Organic nitratesMay precipitate chest pain if withheldHypotensionShould be continued until and including the day of the operation C02CA: Alpha-adrenoreceptor antagonistsRisk of intraoperative floppy iris syndrome (IFIS) with cataract surgery. HypotensionContinue C03: DiureticsPrevent decompensation of congestive heart failure (CHF)Tissue damage and reduced kidney perfusion immediately postoperatively may contribute to the development of hyperkalemia, which may be additive with concurrent potassium-sparing diureticsShould be taken until the day before the operation but discontinued the day of the operation, except in patients with CHF C04: Peripheral vasodilatorsIncreased bleeding riskDiscontinue C07: Beta-blocking agentsReduce ischemia by decreasing myocardial oxygen demand due to increased catecholamine. Help to prevent or control arrhythmiasBradycardia and hypotension\
Interacts with epinephrineRebound hypertension can occur if stopped abruptly\
Monitor blood pressure closely postoperatively\
Only some drugs are available as injections; it may be necessary to change to an alternative drug if an oral route is not availableShould be continued until and including the day of operation C08: Calcium channel blockersMay precipitate chest pain if withheldRebound hypertension can occur if stopped abruptlyMonitor blood pressure closely postoperatively\
Only some drugs are available as injections; it may be necessary to change to an alternative drug if an oral route is not availableShould be continued until and including the day of the operation C09: Agents acting on the renin--angiotensin systemManagement of postoperative hypertensionCan decrease blood pressure at induction of anesthesia, and many drugs within this class have differing half-livesShould be continued until the day before the operation but discontinued on the day of the operation. Last dose should be given 10 h before induction of anesthesia C10: Lipid-modifying agents (non-statin)*Niacin and fibric acid derivatives*: may increase risk of myopathy and rhabdomyolysis, especially when used in combination with statins\
*Bile acid sequestrants*: interfere with the absorption of other medicationsDiscontinue C10AA: HMG-CoA reductase inhibitorsProvide cardiovascular protectionMay increase the risk of myopathy and rhabdomyolysisContinue as usual*G: Genitourinary system and sex hormones* G03A: Hormonal contraceptives for systemic useIncreased risk of postoperative venous thromboembolism (VTE)*Estrogen*-*containing oral contraceptives:* discontinue 4--6 weeks prior to surgery in patients with a high risk of VTE G04BD: Drugs for urinary frequency and incontinenceRisk of arrhythmiasContinue as usual*H: Systemic hormonal preparations, excl. sex hormones and insulins* H02AB: GlucocorticoidsIncreased risk of Addisonian crisis if stoppedImpaired wound healing, increased superficial blood vessels, risk of fractures, infections, and gastrointestinal ulcerContinue---add stress dosing if \> 5 mg prednisone per day (or equivalent) in six months prior to surgery, or on chronic therapy H03: Thyroid therapyNo known perioperative adverse eventsThyroid function should ideally be checked preoperatively to ensure euthyroid stateShould be continued until and including the day of the operation*J: Antiinfectives for systemic use* J05A: Direct-acting antiviralsIncidence of postoperative bacterial complications and sepsis is increased in patients with lower CD4 cell counts if antiretroviral agents are discontinuedMost data regarding surgical morbidity and mortality in the HIV-infected patient predate the availability of effective antiretroviral therapyContinue as usual*L: Antineoplastic and immunomodulating agents* L01AB: Alkyl sulfonatesNo studies suggest that stopping preoperatively reduces the incidence of infection or improves wound healingThe use of lower doses may permit safer use. Monitor renal function and blood count postoperativelyContinue as usual L01XX: Other antineoplastic agentsDiscontinue 3--4 days prior to surgery L02BA: Anti-estrogensIf used for cancer treatment, disease progression may be of concern once treatment interruptedIncreased risk of venous thromboembolismDiscontinue 4--6 weeks prior to surgery in hip and knee surgery L02BG: Aromatase inhibitorsIf used for cancer treatment, disease progression may be of concern once treatment interruptedUnknown perioperative effectsContinue as usual L04AA: Selective immunosuppressantsControlling rheumatoid responseIncreased risk of myelosuppression and wound-healing complications postoperatively*Abatacept:* discontinue prior to surgery at 2 months L04AB: Tumor necrosis factor alpha (TNF-Α) inhibitorsControlling rheumatoid responseIncreased risk of myelosuppression and wound-healing complications postoperativelyDiscontinue prior to surgery at a timing equal to 2--5 half-lives of the respective drug\
Mean half-life (days): infliximab (8--9, 5), etanercept (4--5), adalimumab (15--19)*M: Musculoskeletal system* M03BX: Other centrally acting agentsAbrupt withdrawal of intrathecal baclofen may result in severe sequelae (hyperpyrexia, rebound/exaggerated spasticity, muscle rigidity, and rhabdomyolysis), leading to organ failure and fatalityContinue as usual M04A: Antigout preparationsSurgery could precipitate acute gouty arthropathyContinue as usual. Held on the morning of surgery M05BA: BisphosphonatesEsophagitis in bedridden patientsDiscontinue*N: Nervous system* N02A: OpioidsAbrupt withdrawal can cause yawning, abdominal cramps, nausea, vomiting, insomnia, anxiety, and salivationShould be continued until and including the day of the operation without exception N02B: Other analgesics and antipyreticsAspirin (ASA) withdrawal linked to cardiovascular eventsContinuation may cause perioperative hemorrhageContinue ASA for secondary cardiovascular prevention\
Discontinue ASA for primary cardiovascular prevention N03: AntiepilepticsPossibility of precipitating convulsions if stopped*Phenytoin:* levels may fluctuate in response to perioperative situations\
*Carbamazepine:* interactions with medications administered in the perioperative period\
*Valproic acid:* thrombocytopeniaCheck serum drug levelShould be continued until and including the day of the operation N04: Antiparkinson drugsAvoid symptoms of Parkinson's disease (agitation, rigidity)Metabolite of levodopa, dopamine can cause arrhythmias, hypotension or hypertensionShould be continued until and including the day of the operation N05A: AntipsychoticsWithdrawal symptoms can occur if stopped abruptly plus severe agitationSome agents are associated with QT prolongation, and occasionally cause hypotension or arrhythmiasA routine ECG should be performed on all patients preoperativelyContinue as usual N05AN: LithiumDecreases the release of neurotransmitters and may prolong the effect of neuromuscular blockersClose monitoring of fluid and electrolytes is essential due to the narrow therapeutic index of lithium and the usual changes in electrolyte levels postoperativelyShould be continued until and including the day of the operation N05B: AnxiolyticsContinue these agents to avoid withdrawal; however, the patient will likely have decreased anesthesia requirementsRisk of pharmacokinetic and pharmacodynamic interactions with drugs used in the perioperative settingIf a benzodiazepine becomes necessary, consider using short--medium half-livesContinue if indicated N06AA: Nonselective monoamine reuptake inhibitorsWithdrawal symptoms can occur if stopped abruptlyArrhythmias with anestheticsContinue as usual. Discontinue if arrythmia occurs N06AB: Selective serotonin reuptake inhibitorsWithdrawal symptoms can occur if stopped abruptlyBleeding risk, drug interactionsContinue as usual N06AG: Monoamine oxidase A inhibitorsRisk of withdrawal symptomsInteractions with medications used in the perioperative setting (hypertension)Avoid administration of meperidine/dextromethorphan/ephedrine and monitor closely while on narcotics (potential for reactions consisting of rigidity, hallucinating, fever, confusion, coma, and death)Discontinue N06D: Antidementia drugsThrough their effects on acetylcholinesterase, these agents are likely to exaggerate muscle relaxation during anaesthesia produced by suxamethonium, hence prolonging neuromuscular blockadeThe relevant pharmaceutical manufacturers recommend discontinuation of both of these agents preoperatively to avoid these effects N07C: Antivertigo preparationsContinue as usual*R: Respiratory system* R03: Drugs for obstructive airway diseases*Inhaled bronchodilators:* may precipitate bronchospasm if withheld*Theophylline:* risk of arrhythmias and neurotoxicity*Theophylline*: narrow therapeutic rangeContinue as usual\
*Theophylline:* discontinue evening before surgery*S: Sensory organs* S01: OphthalmologicalsNo known perioperative adverse effectsContinue as usual S02: OtologicalsNo known perioperative adverse effectsContinue as usualV: Various V03AE: Drugs for treatment of hyperkalemia and hyperphosphatemiaNo known perioperative adverse effectsContinue as usual V03AF: Detoxifying agents for antineoplastic treatmentNo known perioperative adverse effectsContinue as usual PhytotherapyNo evidence that phytotherapy improves surgical outcomes*Ephedra:* increases the risk of heart attack and stroke\
*Garlic:* increases the risk of bleeding\
*Ginkgo:* increases the risk of bleeding\
*Ginseng:* lowers blood sugar and increases the risk of bleeding\
*Valerian:* increases the sedative effects of anesthetics and is associated with benzodiazepine-like withdrawal\
*Echinacea:* allergic reactions and immune stimulationShould be discontinued at least one full week prior to the planned surgical procedure*PPIs* proton pump inhibitors, *ECG* electrocardiogram

Validation of the guidelines {#Sec13}
----------------------------

### Sample of patients selected for the observational concordance study {#Sec14}

During the study period, 140 drugs were analyzed; those drugs were taken by 20 Caucasian patients (seven drugs/patient) admitted to the orthopedic surgery unit.

The demographic (age and sex) and clinical (number of comorbidities) characteristics and diagnosis-related groups (DRGs) of the 20 patients are described in Table [2](#Tab2){ref-type="table"}.Table 2Demographic and clinical characteristics of the 20 patientsDRGn (%)SexMedian age (years)Median number of comorbidities per patientMF209---Major joint and limb reattachment procedures for a lower extremity9 (45.0)2778.563.44211---Hip and femur procedures excluding a major joint, age \> 17 years, without complications or comorbidities2 (10.0)20734.5218---Lower extremity and humerus procedures excluding hip, foot, and femur, age \> 17 years, with complications or comorbidities1 (5.0)10453219---Lower extremity and humerus procedures excluding hip, foot, and femur, age \> 17 years, without complications or comorbidities2 (10.0)1147.53251---Fracture, sprain, strain, and dislocation of forearm, hand, or foot, age \> 17 years, without complications or comorbidities1 (5.0)01384807---Anterior and posterior spinal fusion combined, without complications1 (5.0)01864818---Hip replacement without complications4 (20.0)0481.253.75Total20 (100.0)61470.453.60*DRG* diagnosis-related group, *M* male, *F* female

In total, there were 72 major comorbidities in the 20 patients, with an average of 3.6 comorbidities per patient. The most frequently detected comorbidity was hypertension, in 13 patients (65%), followed by depression in six patients (30%), and congestive heart failure and diabetes mellitus in five patients each (25% each). There were also four cases of dyslipidemia (20%) and four of atrial fibrillation (20%). Only three cases of osteoporosis were detected (15%), three of acute myocardial infarction (15%), three of benign prostatic hyperplasia (3%), and three of dementia/Alzheimer's disease (15%). Vertiginous syndrome was observed in two patients (10%), hiatal hernia in two patients (10%), and anemia in two patients (10%). Finally, other comorbidities such as stroke, ulcer, acquired immune deficiency syndrome, Parkinson's disease, neoplasia, insomnia, hypothyroidism, gout, schizophrenia, epilepsy, Crohn's disease, and asthma/chronic obstructive pulmonary disease were detected in 12 patients (60%) (data not shown).

### Drugs reviewed in the study {#Sec15}

The eight observers reviewed 140 drugs. The most prevalent therapeutic groups were group N (nervous system), 43 drugs (30.71%); group C (cardiovascular system), 37 medicines (26.43%); group A (alimentary tract and metabolism), 27 drugs (19.29%); and group B (blood and blood-forming organs), 14 drugs (10%) (Table [3](#Tab3){ref-type="table"}).Table 3Absolute agreement among eight pharmaceutical observers following the application of the guide, listed according to ATC groupMedicine class*n* (%)Kappa valueAgreementA02: Drugs for acid-related disorders16 (11.4)1Almost perfectA07: Antidiarrheals, intestinal anti-inflammatory/anti-infective agents1 (0.7)*p* \< 0.01PoorA10: Drugs used in diabetes8 (5.7)0.69SubstantialA11: Vitamins1 (0.7)1Almost perfectA12: Mineral supplements2 (1.4)0.75SubstantialB01: Antithrombotic agents10 (7.1)0.16SlightB03: Antianemic preparations4 (2.9)0.81Almost perfectC01: Cardiac therapy4 (2.9)1Almost perfectC02: Antihypertensives1 (0.7)1Almost perfectC03: Diuretics11 (7.9)0.51ModerateC05: Vasoprotectives1 (0.7)1Almost perfectC07: Beta-blocking agents1 (0.7)1Almost perfectC08: Calcium channel blockers3 (2.1)1Almost perfectC09: Agents acting on the renin-angiotensin system9 (6.4)0.83Almost perfectC10: Lipid-modifying agents6 (4.3)0.33FairD11: Other dermatological preparations1 (0.7)\< 0.01PoorG03: Sex hormones and modulators of the genital system1 (0.7)1Almost perfectG04: Urologicals2 (1.4)0.55ModerateH02: Corticosteroids for systemic use2 (1.4)1Almost perfectH03: Thyroid therapy3 (2.1)1Almost perfectJ05: Antivirals for systemic use1 (0.7)0.50ModerateL01: Antineoplastic agents1 (0.7)1Almost perfectL02: Endocrine therapy1 (0.7)1Almost perfectL04: Immunosuppressants1 (0.7)1Almost perfectM01: Anti-inflammatory and antirheumatic products1 (0.7)1Almost perfectM04: Antigout preparations1 (0.7)1Almost perfectN02: Analgesics10 (7.1)0.60ModerateN03: Antiepileptics5 (3.6)1Almost perfectN04: Antiparkinson drugs2 (1.4)0.46ModerateN05: Psycholeptics14 (10.0)0.93Almost perfectN06: Psychoanaleptics11 (7.9)0.76SubstantialN07: Other nervous system drugs1 (0.7)0.50ModerateR03: Drugs for obstructive airway diseases1 (0.7)1Almost perfectS01: Ophthalmologicals1 (0.7)1Almost perfectPhytotherapeutics2 (1.4)0.43Moderate

### Agreement between observers {#Sec16}

Table [3](#Tab3){ref-type="table"} shows the percentage of absolute agreement between the eight pharmaceutical observers according to ATC group (*n* = 140 drugs). There was substantial or almost perfect interobserver agreement for the majority of the drug classes in the guide, such as the main anatomical groups H, L, M, R, and S as well as the main therapeutic groups A02, C05, C07, C08, G03, and N03. However, there was only fair or slight interobserver agreement for antidiarrheals, intestinal anti-inflammatory/anti-infective agents, antithrombotic agents, and other dermatological preparations.

### Agreement between each observer and the expert pharmacist {#Sec17}

Table [4](#Tab4){ref-type="table"} shows the agreement between each observer and the gold standard. We obtained an overall kappa value of 0.78 \[95% CI (0.66, 0.89)\], which indicated almost perfect concordance between the observers and the expert pharmacist, and the overall agreement was 89.30% for the 140 drugs.Table 4Concordance between the eight observers and the expert pharmacistObserverKappa valueSE*p*95% CIAgreementObserver 10.820054\< 0.0010.71--0.92Almost perfectObserver 20.830050\< 0.0010.73--0.93Almost perfectObserver 30.750059\< 0.0010.64--0.87SubstantialObserver 40.770060\< 0.0010.65--0.88SubstantialObserver 50.790057\< 0.0010.68--0.90SubstantialObserver 60.810054\< 0.0010.70--0.91Almost perfectObserver 70.740062\< 0.0010.62--0.86SubstantialObserver 80.750061\< 0.0010.63--0.87Substantial*SE* standard error, *95% CI* confidence interval

Discussion {#Sec18}
==========

In this study, we developed a valid guide for the continuity of care in perioperative medication management, based on the available evidence and approved by a committee including specialists and physicians from the Department of Anesthesiology. This guide was validated by demonstrating that its use resulted in high concordance among eight pharmacists in decisions made regarding 140 drugs taken by 20 chronic inpatients. For the set of pharmaceutical interventions considered by the eight observers, we obtained an overall agreement of 86.9% and a kappa value of 0.7. When we compared the decisions made by the individual observers to those made by the expert pharmacist, the kappa value (a measure of the agreement between two observers) increased to 0.8 \[95% CI (0.7, 0.9)\], indicating almost perfect concordance, and the overall agreement was 89.3%.

A similar study was conducted in a tertiary hospital in Australia by Lindsay et al. \[[@CR18]\] during 2013, where the aims were to design and validate deprescribing guidelines for cancer patients in palliative care and to identify potentially inappropriate medicines. That prospective, noninterventional cohort study comprised four major stages (similar to our study): developing the OncPal Deprescribing Guidelines based on current evidence; the prospective recruitment of consecutive palliative cancer inpatients; the assessment of all medications by a panel of medical experts to identify potentially inappropriate medicines; and an evaluation of the guidelines by concordance testing. The OncPal Deprescribing Guidelines matched 94.0% of the expert panel's recommendations for 617 medicines, and the kappa value was 0.8 \[95% CI (0.8, 0.9)\], a similar result to ours. However, the difference from our study was that the Australian observers did not receive a training session regarding the guidelines because they were considered experts. In our study, we included pharmacists with a range of expertise in the evaluations, so the training course was crucial to achieving these great results. However, although concordance was very high for the majority of the medicine classes, it was low for antidiarrheals, intestinal anti-inflammatory/anti-infective agents, antithrombotic agents, and other dermatological preparations. When interpreting our results, it is important to note that the observers had no previous experience with this analysis, and that they carried out the observations that form the basis of this study only after a period of formal training. We feel that with additional experience, the results would have been better in all the drug classes.

It is important to note that his study has various limitations:This study focused only on the diagnosis of each patient undergoing an orthopedic procedure. Thus, previous comorbidities could have affected patient health.This study should have considered patients from different ethnic groups, given that the pharmacokinetics and pharmacodynamics of drugs can vary among ethnic groups \[[@CR20]\].This study was carried out in just one hospital; in the future, the guide should be validated further and its reproducibility should be checked by applying it in different clinical settings in the same hospital and in different hospitals.

In summary, we have developed a guide for the continuity of care in perioperative medication management as a tool to improve the rationalization of medicines in the perioperative environment. Given the high number of medical comorbidities suffered by the elderly, and the associated polypharmacy and perioperative risks, it is important to ensure optimal management of the pre-existing medical conditions of these patients before and during surgery. Applying the guide developed here minimizes chronic disease progression or decompensation, interactions with anesthesia, and perioperative complications. The validation of this guide showed a high level of concordance between the trained observers and the expert who had previously classified the medication. Formal training seems to be essential to assure consistency of medication management, even among pharmacists with different levels of expertise.
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